GS points out that the equal-weight S&P tends to underperform the market weight index sharply before the trend reverses. It cites the market's performance of the two indexes before the bubble's 'pop' to point out that "the trough in 10-year relative underperformance of the equal-weight vs. cap-weight index occurred during the lead-up to the Dot Com bubble (1990-2000)." This saw the equal weight index lag the market weight index by four percentage points (pp) at the trough or the bottom. After the bottom, the differential flipped and the equal weight index led its counterpart by close to seven points (pp). As per Goldman, the four-point shortfall "has been matched during the past decade (2014-2024E) as the aggregate index has been powered by a few mega-cap Tech stocks and AI euphoria."
Linking historical performance trends with investor concentration in mega caps and AI stocks, the bank shares that this "extreme level of market concentration (99th percentile) suggests the magnitude of equal-weight outperformance over the next decade should also be stronger than average." Just how strong can this be? Well GS outlines that the equal weight index can outperform the market weighed index by 8 percentage points. On the flip side, since this is the most bullish forecast, the bank notes that if equal weight index performance reverts to its historical mean over the past 50 years, then "this would imply a less dramatic 2 pp of annualized outperformance."
While stock market math is all good, other factors also drive its performance. November has seen headlines talk about nothing else but the Presidential Election. Post-election stock performance saw some firms, like Elon Musk's car company record stunning gains. Goldman's Shawn Tuteja, who works with exchange-traded funds (ETFs) and baskets, shared some insights about what sectors performed well after the election and whether this outperformance will continue. In a podcast, he outlined that "the biggest themes that we saw play out the day after the election on Wednesday were regional banks and banks getting bought." He shared that "any sectors that were linked to de-regulation, benefited." These include "energy, traditional energy versus renewables" with the former up by 4% while the latter losing roughly 10%.
Tuteja added that "the resilience and strength of US tech over the past couple of days post the election" was a standout from the market's post-election performance in 2016. As to what lies in the future, the Goldman analyst is optimistic. He believes that "what I would expect to come over the next couple of weeks is a continuation on the factor level of the themes that worked post the election." This is because "it takes time for money to be deployed and for themes to play out." According to him, in 2016, "regional banks and big banks rallied for months after the election and they outperformed all of the other sectors in the market." Additionally, while the broader markets might have calmed at a surface level, Tuteja points out that "under the surface, those sector moves become a lot more violent as correlations in the market break, as people start picking winners and losers in the new government regime's policies."
For some bank stocks, you can check out 10 Best Local Bank Stocks To Invest In Now and 10 Best Diversified Bank Stocks to Buy Now.
Within this dynamic environment that will see the Fed continue to tailor its interest rate decisions to the economy and companies adjust to a looser monetary policy, firms might also increase their cash spending. In a note covering spending, Goldman shared that the benchmark S&P index firms can increase their spending to 11% next year from 2024's 8%. This will be driven by rising profits, as the bank believes that earnings "growth alone can explain 40% of next quarter's cash spending growth."
Just like it expects equities performance to broaden in the future, the bank also posits that the "typical stock should close the earnings growth gap with the mega-cap tech stocks." Finally, on the topic of mergers and acquisitions, which slowed down in the wake of historic interest rates, GS is optimistic. It expects "cash M&A will rebound by 20% in 2025," but cautions that "the potential for tariffs, regulatory changes, and corporate tax reform could meaningfully shift these forecasts."
To make our list of Goldman Sachs' top growth investment stocks, we used the bank's recent list of stocks and picked out those with a growth investment ratio of 70% or higher. This ratio is defined as the ratio of capital expenditure and R&D spending excluding depreciation over a firm's cash flow from operations.
For these stocks, we also mentioned the number of hedge fund investors. The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points. (see more details here).
A pharmacist delivering a specific medication to a patient in a specialty pharmacy.
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a Massachusetts-based biotechnology company that develops treatments for fibrosis, sickle cell disease, thalassemia, and other ailments. It is operationally profitable, which means that Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)'s hypothesis is based on its ability to maintain share with existing drugs and the ability to launch new treatments to grow revenue. On the former front, the firm is quite vulnerable as it depends to a large extent on its cystic fibrosis treatment TRIKAFTA to generate revenue. As of H1 2024, 92% of Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)'s revenue came through the cystic fibrosis treatment. Consequently, not only does the firm have to ensure that the fibrosis drug does not face competition from rivals, but it also has to maintain a robust pipeline to reduce income statement risk. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)'s CASGEVY is the world's first gene-editing-based therapy for sickle cell disease and is in the early commercial stages. The firm also has kidney disease, diabetes, and neuropathy treatments in phase three trials.
PGIM Jennison mentioned Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) in its Q2 2024 investor letter. Here is what the fund said:
"Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a commercial stage biopharmaceutical with a core franchise of small molecule CFTR modulators for cystic fibrosis (CF), a genetic and progressively fatal respiratory disease. Vertex has built a unique and unrivaled market position as the dominant market leader in CF, having created and expanded the market into a nearly $10B franchise and growing. Later this year, we expect them to receive approval for their next-gen CF triple therapy, which we think will drive top-line growth and margin expansion in 2025 onwards. Vertex is also developing an acute and chronic pain franchise. Vertex reported positive Phase 3 data in acute pain and Phase 2 data in chronic pain earlier this year; the FDA filing in acute pain has been completed, and pending approval, Vertex expects to launch in acute pain in early 2025. Beyond CF and pain, Vertex has focused its pipeline around genetically driven diseases with the potential for a transformative clinical benefit. It currently spans 5 disease verticals: sickle cell/beta thalassemia, type 1 diabetes, APOL-1 kidney disease, IgA nephropathy (from the recent acquisition of Alpine Immune Sciences), and alpha-1 antitrypsin disease. Vertex has had a strong start to the year and has delivered positively on several clinical trial readouts, as well as beat Q1 revenue estimates and maintained what was a better than expected '24 guidance. Vertex has a busy catalyst calendar in 2H24 which include next-gen CF approval, acute pain approval for their first-in-class pain drug, and additional data sets in chronic pain."
Overall, VRTX ranks 6th on our list of Goldman Sachs' top growth investors. While we acknowledge the potential of VRTX as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than VRTX but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock.
READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock
Disclosure: None. This article is originally published at Insider Monkey.